Supernus (SUPN) director exits 4,475 shares after RSU vesting and sales

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. director Bethany Sensenig reported a set of stock transactions involving restricted stock units and common shares of SUPN. On February 19, 2026, she exercised 4,475 restricted stock units, receiving the same number of common shares at a stated price of $0.00 per share as the units vested.

That same day, she conducted open-market sales of common stock in two blocks: 1,217 shares at a weighted average price of $50.31 (with individual trades between $49.83 and $50.71) and 3,258 shares at a weighted average price of $51.27 (with trades between $50.98 and $51.56). These sales, totaling 4,475 shares, were made under a Rule 10b5-1 trading plan adopted on May 15, 2025, and left her with 0 shares of common stock directly owned after the reported transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sensenig Bethany

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		M		4,475	A	$0	4,475	D
Common Stock	02/19/2026		S(1)		1,217	D	$50.31(2)	3,258	D
Common Stock	02/19/2026		S(1)		3,258	D	$51.27(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(4)	02/19/2026		M			4,475	(5)	(5)	Common Stock	4,475	$0	0	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.83 to $50.71. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.98 to $51.56. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

4. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

5. These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2026.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did SUPN director Bethany Sensenig report on February 19, 2026?

Bethany Sensenig reported exercising 4,475 restricted stock units into common stock, then selling 4,475 common shares in open-market transactions. These moves reflect a derivative exercise followed by complete sale of the resulting shares on the same date.

At what prices did Bethany Sensenig sell Supernus Pharmaceuticals (SUPN) shares?

She sold 1,217 SUPN shares at a weighted average price of $50.31, with trades from $49.83 to $50.71, and 3,258 shares at a weighted average of $51.27, with trades from $50.98 to $51.56, according to the Form 4 disclosure.

How many Supernus (SUPN) shares did Bethany Sensenig hold after these Form 4 transactions?

After completing the reported exercise and sales, Bethany Sensenig directly owned 0 shares of Supernus common stock. The 4,475 shares acquired from restricted stock units were fully sold through the two open-market transactions disclosed in the filing.

Were Bethany Sensenig’s SUPN stock sales under a Rule 10b5-1 trading plan?

Yes. The Form 4 states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on May 15, 2025. Such plans pre-schedule trades, helping insiders systematically sell or buy shares over time.

What did the Form 4 say about Bethany Sensenig’s restricted stock units in SUPN?

Each restricted stock unit represented the right to receive one share of Supernus common stock upon vesting. The filing notes these units were settled in common stock upon vesting, which occurred on February 19, 2026, creating 4,475 shares before they were sold.